PMID- 29290996
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 63
DP  - 2017 Dec 5
TI  - The role of talin2 in breast cancer tumorigenesis and metastasis.
PG  - 106876-106887
LID - 10.18632/oncotarget.22449 [doi]
AB  - Recent studies show that talin2 has a higher affinity to beta-integrin tails and is 
      indispensable for traction force generation and cell invasion. However, its roles 
      in cell migration, cancer cell metastasis and tumorigenesis remain to be 
      determined. Here, we used MDA-MB-231 human breast cancer cells as a model to 
      define the roles of talin2 in cell migration, invasion, metastasis and 
      tumorigenesis. We show here that talin2 knockdown (KD) inhibited cell migration 
      and focal adhesion dynamics, a key step in cell migration, and that talin2 
      knockout (KO) inhibited cell invasion and traction force generation, the latter 
      is crucial for cell invasion. Re-expression of talin2(WT) in talin2-KO cells 
      restored traction force generation and cell invasion, but that of talin2(S339C), 
      a beta-integrin-binding deficient mutant, did not. Moreover, talin2 KO (or KD) 
      suppressed tumorigenesis and metastasis in mouse xenograft models. However, 
      surprisingly, re-expression of talin2(WT) in talin2-KO cells did not rescue 
      tumorigenesis. Thus, talin2 is required for breast cancer cell migration, 
      invasion, metastasis and tumorigenesis, although exogenous expression of high 
      levels of talin2 could inhibit tumorigenesis.
FAU - Li, Liqing
AU  - Li L
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
FAU - Li, Xiang
AU  - Li X
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
FAU - Qi, Lei
AU  - Qi L
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
FAU - Rychahou, Piotr
AU  - Rychahou P
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
FAU - Jafari, Naser
AU  - Jafari N
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
FAU - Huang, Cai
AU  - Huang C
AD  - Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.
AD  - Department of Pharmacology and Nutritional Sciences, University of Kentucky, 
      Lexington, KY 40506, USA.
LA  - eng
GR  - P30 CA177558/CA/NCI NIH HHS/United States
GR  - R01 CA195573/CA/NCI NIH HHS/United States
GR  - R01 GM122994/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171106
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5739781
OTO - NOTNLM
OT  - cell migration
OT  - invasion
OT  - metastasis
OT  - talin2
OT  - tumor growth
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest to disclose.
EDAT- 2018/01/02 06:00
MHDA- 2018/01/02 06:01
PMCR- 2017/12/05
CRDT- 2018/01/02 06:00
PHST- 2017/08/06 00:00 [received]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2018/01/02 06:00 [entrez]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/01/02 06:01 [medline]
PHST- 2017/12/05 00:00 [pmc-release]
AID - 22449 [pii]
AID - 10.18632/oncotarget.22449 [doi]
PST - epublish
SO  - Oncotarget. 2017 Nov 6;8(63):106876-106887. doi: 10.18632/oncotarget.22449. 
      eCollection 2017 Dec 5.